Nord/LB Reiterates €92.00 Price Target for Fresenius Medical Care AG & Co. KGaA (FME)

Nord/LB set a €92.00 ($106.98) price objective on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a research note issued to investors on Friday morning, Borsen Zeitung reports. The firm currently has a buy rating on the stock.

Other equities analysts also recently issued research reports about the company. JPMorgan Chase & Co. set a €83.20 ($96.74) target price on Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research report on Monday, February 18th. HSBC set a €87.00 ($101.16) target price on Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research report on Wednesday, February 13th. Deutsche Bank set a €100.00 ($116.28) target price on Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research report on Tuesday, February 12th. Berenberg Bank set a €88.85 ($103.31) target price on Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research report on Tuesday, February 5th. Finally, UBS Group set a €82.00 ($95.35) target price on Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research report on Wednesday, January 30th. Eight analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Fresenius Medical Care AG & Co. KGaA has an average rating of Buy and a consensus target price of €83.96 ($97.62).

ETR FME opened at €74.44 ($86.56) on Friday. The company has a market capitalization of $22.62 billion and a PE ratio of 11.54. Fresenius Medical Care AG & Co. KGaA has a 1-year low of €55.44 ($64.47) and a 1-year high of €91.74 ($106.67). The company has a current ratio of 1.25, a quick ratio of 0.96 and a debt-to-equity ratio of 58.49.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Featured Article: How does new data get added to a blockchain?

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.